Overview

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2036-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

BeOne Medicines

Treatments:

Aromatase Inhibitors
Cyclin-Dependent Kinase Inhibitor p16
Estrogen Receptor Antagonists